Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Risk & Volatility

Adamis Pharmaceuticals Corporation has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 2.51, indicating that its stock price is 151% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Adamis Pharmaceuticals Corporation and Innoviva, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adamis Pharmaceuticals Corporation 0 0 3 0 3.00
Innoviva 1 2 1 0 2.00

Adamis Pharmaceuticals Corporation currently has a consensus price target of $9.83, indicating a potential upside of 107.02%. Innoviva has a consensus price target of $13.00, indicating a potential upside of 3.26%. Given Adamis Pharmaceuticals Corporation’s stronger consensus rating and higher probable upside, research analysts clearly believe Adamis Pharmaceuticals Corporation is more favorable than Innoviva.

Profitability

This table compares Adamis Pharmaceuticals Corporation and Innoviva’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adamis Pharmaceuticals Corporation -158.51% -69.03% -47.51%
Innoviva 52.91% -33.55% 26.40%

Earnings and Valuation

This table compares Adamis Pharmaceuticals Corporation and Innoviva’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Adamis Pharmaceuticals Corporation $6.47 million 23.02 -$19.43 million N/A N/A
Innoviva $133.57 million 10.31 $59.53 million $0.87 14.47

Innoviva has higher revenue and earnings than Adamis Pharmaceuticals Corporation.

Insider & Institutional Ownership

10.1% of Adamis Pharmaceuticals Corporation shares are owned by institutional investors. Comparatively, 70.0% of Innoviva shares are owned by institutional investors. 9.6% of Adamis Pharmaceuticals Corporation shares are owned by company insiders. Comparatively, 1.6% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Innoviva beats Adamis Pharmaceuticals Corporation on 7 of the 12 factors compared between the two stocks.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

About Innoviva

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.